EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control

Maria Xanthopoulou iD, Paschalis Evangelidis iD, Dimitrios Poulis, Eleni Gavriilaki iD, Nikolaos Kotsiou iD, Christina Antza iD, Vasilios Kotsis iD, Chrysoula Doxani iD, Theodoros Mprotsis iD, Elias Zintzaras, Panagiota Anyfanti iD

Pharmaceuticals · 12.03.2026 · 19 (3) · 462

DOI: 10.3390/ph19030462 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 12.03.2026. Verfasst von Maria Xanthopoulou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 56429 Thessaloniki, Greece. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is cumulative evidence that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can offer cardiovascular protection extending beyond glucose-lowering and weight reduction, but the underlying mechanisms contributing to these effects remain incompletely understood. Modulation of platelet function might contribute to the aforementioned benefits. In the current literature review article, we synthesized available preclinical and clinical data evaluating the effects of GLP-1 RAs on platelet activation and function. Preclinical data indicate that GLP-1 RAs might decrease platelet activation via both GLP-1 receptor-dependent and -independent mechanisms with the involvement of cyclic adenosine monophosphate signaling, increase in nitric oxide bioavailability, and suppression of thromboxane-mediated pathways, particularly under inflammatory or shear-stress conditions. Additionally, clinical studies, despite being limited and heterogeneous, support a reduction in platelet activation markers, even independently of glycemic control or weight loss. However, most of them are characterized by small sample sizes and significant heterogeneity among them. In summary, existing evidence suggests that GLP-1 RAs exhibit potential antiplatelet effects that could contribute to their cardioprotective profile. Larger, well-designed clinical studies are crucial to better understand the clinical importance of platelet modulation by GLP-1 RAs and their potential implications for cardiovascular risk reduction.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistsatherothrombosiscardiovascular diseaseendotheliumnitric oxideplatelet activationplatelet aggregationthrombosisthromboxane

Autor:innen und Institutionen

  • Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 56429 Thessaloniki, Greece.
  • Second Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
  • Department of Biomathematics, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
  • Center for Clinical Evidence Synthesis, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA.
  • Pharmacology and Drug Development Program, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111, USA.

ORCID-Profile: Maria Xanthopoulou, Paschalis Evangelidis, Eleni Gavriilaki, Nikolaos Kotsiou, Christina Antza, Vasilios Kotsis, Chrysoula Doxani, Theodoros Mprotsis, Panagiota Anyfanti

Zitieren

APA

Xanthopoulou, M., Evangelidis, P., Poulis, D., Gavriilaki, E., Kotsiou, N., Antza, C., Kotsis, V., Doxani, C., Mprotsis, T., Zintzaras, E., & Anyfanti, P. (2026). Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control. Pharmaceuticals, 19(3), 462. https://doi.org/10.3390/ph19030462

Vancouver

Xanthopoulou M, Evangelidis P, Poulis D, Gavriilaki E, Kotsiou N, Antza C, et al. Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control. Pharmaceuticals. 2026;19(3):462. doi:10.3390/ph19030462

BibTeX
@article{Xanthopoulou2026,
  author = {Xanthopoulou, Maria and Evangelidis, Paschalis and Poulis, Dimitrios and Gavriilaki, Eleni and Kotsiou, Nikolaos and Antza, Christina and Kotsis, Vasilios and Doxani, Chrysoula and Mprotsis, Theodoros and Zintzaras, Elias and Anyfanti, Panagiota},
  title = {Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {3},
  pages = {462},
  doi = {10.3390/ph19030462}
}
Kostenlos starten →